No Data
No Data
Zymeworks (NASDAQ:ZYME) Shareholders Are up 9.5% This Past Week, but Still in the Red Over the Last Three Years
Zymeworks Inc. (NASDAQ:ZYME) shareholders should be happy to see the share price up 19% in the last month. But that doesn't change the fact that the returns over the last three years have been
Zymeworks to Unveil Q2 2024 Results and Drug Progress
Zymeworks To Report Second Quarter 2024 Financial Results and Host Conference Call on August 1, 2024
VANCOUVER, British Columbia, July 11, 2024 (GLOBE NEWSWIRE) -- Zymeworks Inc. (NASDAQ:ZYME), a clinical-stage biotechnology company developing a diverse pipeline of novel, multifunctional biotherapeutics to improve the
H.C. Wainwright Maintains Zymeworks(ZYME.US) With Hold Rating, Maintains Target Price $10
H.C. Wainwright analyst Robert Burns maintains $Zymeworks(ZYME.US)$ with a hold rating, and maintains the target price at $10.According to TipRanks data, the analyst has a success rate of 24.0% and a
Zymeworks Analyst Ratings
Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating 06/18/2024 17.1% HC Wainwright & Co. $10 → $10 Reiterates Buy → Buy 06/06/2024 17.1% HC Wainwright & Co. $
Zymeworks ZW171 IND for Mesothelin-expressing Cancers Cleared by FDA